Skip to main content
NASDAQ:VIRX

Viracta Therapeutics Competitors

$7.68
+0.02 (+0.26 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.57
$8.50
50-Day Range
$7.55
$11.02
52-Week Range
$3.92
$24.80
Volume395,053 shs
Average Volume723,570 shs
Market Capitalization$39.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Viracta Therapeutics (NASDAQ:VIRX) Vs. IPA, GANX, LBPH, EVAX, LGVN, and UPC

Should you be buying VIRX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Viracta Therapeutics, including ImmunoPrecise Antibodies (IPA), Gain Therapeutics (GANX), Longboard Pharmaceuticals (LBPH), Evaxion Biotech A/S (EVAX), Longeveron (LGVN), and Universe Pharmaceuticals (UPC).

ImmunoPrecise Antibodies (NASDAQ:IPA) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares ImmunoPrecise Antibodies and Viracta Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A
Viracta TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for ImmunoPrecise Antibodies and Viracta Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoPrecise Antibodies01002.00
Viracta Therapeutics00403.00

Viracta Therapeutics has a consensus price target of $33.50, indicating a potential upside of 336.20%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viracta Therapeutics is more favorable than ImmunoPrecise Antibodies.

Profitability

This table compares ImmunoPrecise Antibodies and Viracta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoPrecise AntibodiesN/AN/AN/A
Viracta TherapeuticsN/AN/AN/A

Summary

Viracta Therapeutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Viracta Therapeutics (NASDAQ:VIRX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Viracta Therapeutics and Gain Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Viracta Therapeutics and Gain Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viracta Therapeutics00403.00
Gain Therapeutics00203.00

Viracta Therapeutics presently has a consensus target price of $33.50, indicating a potential upside of 336.20%. Gain Therapeutics has a consensus target price of $30.00, indicating a potential upside of 212.17%. Given Viracta Therapeutics' higher possible upside, analysts plainly believe Viracta Therapeutics is more favorable than Gain Therapeutics.

Profitability

This table compares Viracta Therapeutics and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viracta TherapeuticsN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Summary

Viracta Therapeutics beats Gain Therapeutics on 2 of the 2 factors compared between the two stocks.

Longboard Pharmaceuticals (NASDAQ:LBPH) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Longboard Pharmaceuticals and Viracta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longboard PharmaceuticalsN/AN/AN/AN/AN/A
Viracta TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Longboard Pharmaceuticals and Viracta Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longboard Pharmaceuticals00503.00
Viracta Therapeutics00403.00

Longboard Pharmaceuticals currently has a consensus price target of $32.75, suggesting a potential upside of 295.05%. Viracta Therapeutics has a consensus price target of $33.50, suggesting a potential upside of 336.20%. Given Viracta Therapeutics' higher probable upside, analysts plainly believe Viracta Therapeutics is more favorable than Longboard Pharmaceuticals.

Profitability

This table compares Longboard Pharmaceuticals and Viracta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Longboard PharmaceuticalsN/AN/AN/A
Viracta TherapeuticsN/AN/AN/A

Viracta Therapeutics (NASDAQ:VIRX) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Valuation and Earnings

This table compares Viracta Therapeutics and Evaxion Biotech A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/AN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/AN/AN/A

Profitability

This table compares Viracta Therapeutics and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viracta TherapeuticsN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Viracta Therapeutics and Evaxion Biotech A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viracta Therapeutics00403.00
Evaxion Biotech A/S00203.00

Viracta Therapeutics currently has a consensus price target of $33.50, suggesting a potential upside of 336.20%. Evaxion Biotech A/S has a consensus price target of $18.00, suggesting a potential upside of 221.43%. Given Viracta Therapeutics' higher probable upside, equities research analysts clearly believe Viracta Therapeutics is more favorable than Evaxion Biotech A/S.

Summary

Viracta Therapeutics beats Evaxion Biotech A/S on 2 of the 2 factors compared between the two stocks.

Viracta Therapeutics (NASDAQ:VIRX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Viracta Therapeutics and Longeveron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viracta TherapeuticsN/AN/AN/A
LongeveronN/AN/AN/A

Earnings & Valuation

This table compares Viracta Therapeutics and Longeveron's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/AN/AN/AN/A
LongeveronN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Viracta Therapeutics and Longeveron, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viracta Therapeutics00403.00
Longeveron0000N/A

Viracta Therapeutics currently has a consensus price target of $33.50, suggesting a potential upside of 336.20%. Given Viracta Therapeutics' higher possible upside, equities analysts plainly believe Viracta Therapeutics is more favorable than Longeveron.

Summary

Viracta Therapeutics beats Longeveron on 2 of the 2 factors compared between the two stocks.

Viracta Therapeutics (NASDAQ:VIRX) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Viracta Therapeutics and Universe Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viracta Therapeutics00403.00
Universe Pharmaceuticals0000N/A

Viracta Therapeutics currently has a consensus target price of $33.50, indicating a potential upside of 336.20%. Given Viracta Therapeutics' higher probable upside, equities research analysts plainly believe Viracta Therapeutics is more favorable than Universe Pharmaceuticals.

Valuation & Earnings

This table compares Viracta Therapeutics and Universe Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/AN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Viracta Therapeutics and Universe Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viracta TherapeuticsN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/A

Summary

Viracta Therapeutics beats Universe Pharmaceuticals on 2 of the 2 factors compared between the two stocks.


Viracta Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.93+5.4%$152.01 millionN/A0.00Gap Down
GANX
Gain Therapeutics
1.7$9.61+6.3%$114.14 millionN/A0.00Earnings Announcement
LBPH
Longboard Pharmaceuticals
1.9$8.29+5.7%$112.63 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.60+5.4%$107.51 millionN/A0.00News Coverage
Gap Up
LGVN
Longeveron
0.0$5.30+1.9%$100.47 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.24+4.6%$70.47 millionN/A0.00Gap Down
VRDN
Viridian Therapeutics
1.7$17.42+0.6%$68.08 millionN/A0.00News Coverage
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.59+6.8%$46.18 millionN/A0.00Gap Up
CUBT
Curative Biotechnology
0.0$0.11+3.9%$44.64 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$4.79+1.7%$39.90 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.4$17.00+2.4%$39.73 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.36+4.8%$39.58 millionN/A0.00Gap Down
VYNT
Vyant Bio
0.0$3.33+13.5%$36.65 millionN/A0.00Upcoming Earnings
News Coverage
Gap Down
MYMD
MyMD Pharmaceuticals
0.0$3.39+7.4%$28.23 millionN/A0.00Upcoming Earnings
Gap Up
VLON
Vallon Pharmaceuticals
0.0$3.66+1.4%$24.93 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.89+1.0%$19.24 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.16+2.5%$18.37 millionN/A0.00
PALI
Palisade Bio
0.0$3.76+22.3%$10.84 millionN/A0.00Upcoming Earnings
High Trading Volume
Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.30+1.3%$0.00N/A0.00Earnings Announcement
Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00
SCPS
Scopus BioPharma
1.4$5.94+13.0%$0.00N/A0.00Gap Down
VERA
Vera Therapeutics
0.0$11.50+0.8%$0.00N/A0.00High Trading Volume
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.